Page 7 - Graphite Bio News Today

Fulcrum Therapeutics offered few details about the clinical hold the FDA placed on its Phase 1b test of its sickle cell disease drug. Graphite Bio, Intellia Therapeutics, and Sangamo Therapeutics also encountered setbacks to their sickle cell programs.

BioPharma

Read more about Reuters Science News Summary on Devdiscourse

A study published on Thursday explored the genetic dynamics of people in Norway, Sweden and Denmark dating back two millennia based on 297 genomes from ancient human remains and data from 16,638 modern Scandinavian men and women. Former astronaut Cunningham, member of first crewed Apollo flight, dies at age 90 Former U.S. astronaut Walter Cunningham, who flew to space aboard Apollo 7 in 1968 on the inaugural crewed Apollo mission that paved the way for the first human moon landing nine months ...

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. Following the market opening Friday, the Dow t...

Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.

Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious adverse event in the first patient dosed, sending its shares down nearly 48% in after hours trading.

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. The Dow traded up 1.69% to 33,488.01...

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. The Dow traded up 2.14% to 33,634.19...

(Reuters) - Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious a...